HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced it has submitted a De Novo request to the U.S. Food and Drug Administration seeking ...
New understanding about the pathophysiology of the condition, along with new clinical trial endpoints for approval, have ...
Alternative pathway blockade via factor B inhibition limits C3 cleavage, amplification loop activity, and downstream membrane ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results